TUESDAY, March 18, 2025 (HealthDay News) -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of ...

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III clinical trials-BRAVE-AA1 and BRAVE-AA2-have confirmed that ...

So, we now have two FDA-approved JAK inhibitors for severe alopecia areata. Summer of 2022, we saw the approval of baricitinib, which is a JAK1/2 inhibitor for adults with severe alopecia areata.

Two JAK inhibitors were recently approved by the United States Food and Drug Administration for severe alopecia areata. Baricitinib, or Olumiant (Eli Lilly/Incyte), was approved for severe ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata ... JAK1/2 inhibitor Olumiant (baricitinib) – was turned ...

The US Food and Drug Administration (FDA) on June 13 (2022) approved a drug called baricitinib as the first oral tablet for treating severe alopecia areata, an autoimmune disorder affecting more ...